Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Spelman

Showing results (221-230 of 266) with videos related to

Pageof 27
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Eclinicalmedicine|January 9, 2023
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019Daniela K van Santen, Rachel Sacks-Davis, Ashleigh Stewart, et al.
BMC Public Health|December 19, 2024
Protektem pikinini blong yu trial: protocol for a single arm field trial to assess the effectiveness of treating-all pregnant women with hepatitis B infection with tenofovir prophylaxis to prevent mother-to-child transmission in Vanuatu, 2024-2025Leila Bell, Aleesha Kalulu, Kali Ameara, et al.
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
Multiple Sclerosis and Related Disorders|April 10, 2026
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885]Helmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 27

Showing results (221-230 of 266) with videos related to

Sort By:
Pageof 27
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 23, 2023
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiersLars Forsberg, Tim Spelman, Pernilla Klyve, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Eclinicalmedicine|January 9, 2023
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019Daniela K van Santen, Rachel Sacks-Davis, Ashleigh Stewart, et al.
BMC Public Health|December 19, 2024
Protektem pikinini blong yu trial: protocol for a single arm field trial to assess the effectiveness of treating-all pregnant women with hepatitis B infection with tenofovir prophylaxis to prevent mother-to-child transmission in Vanuatu, 2024-2025Leila Bell, Aleesha Kalulu, Kali Ameara, et al.
The Lancet. HIV|January 15, 2024
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studiesRachel Sacks-Davis, Daniela K van Santen, Anders Boyd, et al.
Multiple Sclerosis and Related Disorders|April 10, 2026
Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885]Helmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
JAMA Neurology|February 10, 2015
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosisAnna He, Tim Spelman, Vilija Jokubaitis, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 27